One Injection Instead of Twenty-Eight

Someone with type 2 diabetes on basal-bolus insulin injects four or more times a day — roughly 28 times a week. A trial of 679 people tested replacing that with one weekly injection combining insulin icodec and semaglutide. Blood sugar control matched. Weight fell 6.72 kg further. And serious low blood sugar episodes dropped by 88%.^[1]

What was compared

IcoSema is a fixed combination of a once-weekly basal insulin and semaglutide in a single injection. The comparator was basal-bolus therapy — long-acting insulin plus mealtime injections — which is the standard escalation when other treatments stop controlling type 2 diabetes, and the most demanding regimen in common use.

Note what the first row says and does not say. On blood sugar, the combination matched basal-bolus insulin rather than beating it. Everything else in the table is where the advantage lies.

Why the hypoglycemia row matters most

Going from 2.23 episodes per person-year to 0.21 means the average person on basal-bolus therapy had roughly two serious episodes a year, and the average person on the combination had one every five years. That is not an incremental improvement in a laboratory value — it is the removal of the main thing that makes insulin treatment frightening.

The mechanism is visible in the row above it. Participants on the combination needed 270 fewer units of insulin a week, because the semaglutide component was doing work the insulin would otherwise have to do. Less insulin, less hypoglycemia.

The finding nobody measured

One injection a week instead of roughly twenty-eight.

That does not appear as an endpoint anywhere in the trial, and it is what a person currently on basal-bolus insulin would notice first. Mealtime injections structure a day: they require carrying supplies, calculating doses against what is about to be eaten, injecting in restaurants and at work, and remembering every time.

Trials measure HbA1c because it is measurable. The burden of a regimen is harder to quantify and is frequently what determines whether someone follows it — a theme running through this register, from how few people are still taking these drugs at a year to what patients say about the experience.

What it costs

• Gastrointestinal disorders affected 44% of the combination group — the familiar cost of the semaglutide component, in a population not previously exposed to it.
• It is a fixed combination. The two components cannot be titrated independently, which is a real loss of flexibility for a clinician managing someone whose insulin needs change.
• Fifty-two weeks, with no cardiovascular or other outcome data.
• 59% men, mean age 59.6 — a different profile from most trials in this field, and closer to the population actually on basal-bolus therapy.
• Novo Nordisk makes both components.

The honest summary is narrow and substantial. For someone with type 2 diabetes whose regimen has escalated to multiple daily injections, this trial suggests a weekly combination holds blood sugar equally well while removing weight, insulin and most of the hypoglycemia. It says nothing about anyone earlier in the disease, and nothing about long-term outcomes.